Remidio unveils PRISTINE OBM 12 with automatic capture for accurate pediatric measurements

2026-07-16 07:46:17 Health and Fitness

666

Mumbai, 19th December 2025: Myopia is rising at an unprecedented rate globally, affecting nearly 30 percent of the world's population today and projected to reach 50 percent by 2050. India mirrors this trend, with childhood myopia growing sharply from about 7 percent to nearly 21 percent in urban regions within a decade. Early onset myopia increases the risk of complications such as retinal detachment, glaucoma, and myopic maculopathy, making accurate and consistent monitoring essential.

Clinicians face several barriers in managing pediatric myopia, difficulty capturing reliable measurements from young children, high variability between devices, limited access to axial length tools outside tertiary centers, and long wait times in high-volume clinics. Many practices still rely primarily on refraction, which does not adequately track true myopia progression.

The PRISTINE OBM 12 addresses these challenges directly. It brings axial length, full biometry, and autorefraction into one automated, child-friendly platform. The device provides 12 parameters within seconds and integrates smoothly with EMR systems, allowing for objective and evidence-based monitoring.

Automatic alignment and auto-capture ensure that measurements are taken only when fixation is accurate, improving repeatability and reducing technician workload. By unifying autorefraction and anterior segment biometry into a single workflow, the OBM 12 minimizes inter-device variation and streamlines clinic operations.

Its compact design and intuitive interface allow deployment from tertiary hospitals to secondary and community clinics, expanding access to high-quality pediatric myopia assessment.

Anand Sivaraman, CEO of Remidio Innovative Solutions, stated, Anand Sivaraman stated, "With the PRISTINE OBM 12, we focused on building precision into every step of the measurement process. Advanced automation, including automated alignment, 3D eye tracking, and intelligent auto-capture, is designed to standardize measurements and minimize variability. This technology-driven approach improves repeatability, reduces dependence on operator skill, and supports faster, more confident clinical decision-making in pediatric myopia care."

Leading Pediatric Ophthalmologist and Director or Baroda Children Eye Care, Dr Jitendra Jethani added, "The Pristine OBM 12 represents a meaningful leap in myopia care. Its fully automated acquisition with 3D eye tracking ensures consistently accurate biometry and refraction, even in young children or patients with unstable fixation. By capturing all 12 essential parameters in a single scan, it eliminates operator variability and provides reliable data under real world, accommodation challenging conditions.

This level of precision is invaluable for early intervention and long term myopia management."

Dr Pavan Verkicharla, Scientist of Myopia Research and Head and Consultant Optometrist at LV Prasad Eye Institute, Hyderabad, said, " Myopia research clearly shows that axial length is a key marker of monitoring progression. In our validation, the PRISTINE OBM12 showed strong agreement with established standard of care Biometer. As expected, the precision is higher on Pristine OBM 12 compared to manual, non contact Biometer in the market today. By integrating axial length, full biometry, and refraction into a single workflow, it enables more objective monitoring and better clinical interpretation of progression, supporting informed long-term myopia management. This level of performance allows high-quality myopia assessment to scale beyond specialist clinics, including school screening programs and community settings."

With the OBM 12, Remidio strengthens its commitment to scalable, clinically robust technologies that support early detection and standardized monitoring of a rapidly growing global and national health concern.

About Remidio

Today, the human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.

With CE-marked, FDA 510(k)-registered devices, our solutions have screened 16 million+ patients across 55 countries, integrating teleophthalmology and AI for fast, accurate diagnoses. Our innovative retinal imaging solutions ensure precision and efficiency in clinical workflows.

Our journey began humbly - thanks to the chance meeting of our founder, with a mission driven ophthalmologist, who brought into focus the need for decentralizing eye testing with simple to use and affordable devices. That conversation, 15 years back, sparked a vision to make high-quality preventive care accessible to all.

Guided by innovation, empathy, and a commitment to global impact, our journey is just beginning!